CytomX Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2008)

Organization Overview

First Clinical Trial
2017
NCT03013491
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CytomX Therapeutics | CytomX Therapeutics, Inc | CytomX Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (5)

cx-072 (3 trials)

cx-2009 (2 trials)

cx-2029 (1 trial)

ipilimumab (yervoy) (2 trials)

vemurafenib (zelboraf) (1 trial)

Drugs in Phase 1 Trials (2)

cx-188 (1 trial)

cx-904 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Endometrial Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 7